TAMOXIFEN CYP2D6 BLOOD

image not found

NABL Cap Accredited    
This test analyzes CYP2D6 gene variations in the blood to determine how effectively a patient can metabolize Tamoxifen. It helps evaluate whether the drug will convert properly into its active form, which is essential for optimal breast cancer treatment. The test supports personalized therapy decisions and helps identify patients who may need alternative medications. Metropolis Healthcare performs this genetic analysis using advanced molecular techniques for precise and clinically relevant results

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 6,995.00

Sample Type: EDTA Whole Blood , (Mtb Complex) Bottle

Fasting Not Required


Notes: T0034

Frequently Asked Questions (FAQ's):

What does the Tamoxifen CYP2D6 test measure?
It identifies CYP2D6 gene variants that affect how your body metabolizes Tamoxifen.

Why is this test important for patients on Tamoxifen?
It helps predict treatment effectiveness by determining if you can convert Tamoxifen into its active form.

Do I need to fast before this test?
No, fasting is not required for a CYP2D6 genetic test.

Who should undergo this test?
Patients starting Tamoxifen therapy or those not responding adequately to current treatment.

How does Metropolis Healthcare perform this test?
Metropolis Healthcare uses advanced molecular genetic methods to detect CYP2D6 variations accurately.

Can this test help guide medication choices?
Yes, results help doctors decide the most effective hormonal therapy for breast cancer management.

Does this test diagnose cancer?
No, it evaluates drug metabolism, not cancer presence.

Are Metropolis Healthcare reports reliable?
Yes, they follow strict quality standards and use validated molecular platforms for accurate genotyping.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab